As the autoimmune background represents the common etiopathogenetic denominator of type 1 diabetes (T1D) and thyroid diseases (TD), similarly the goal of replacement therapy for hypothyroidism and T1DM is to mimic the physiological hormonal secretion by introducing the missing hormone externally, which in the case of thyroid diseases causing hypothyroidism will be Levothyroxine (L-T4) and for T1D, insulin. In the field of diabetology, pharmacological and technological research aims at restoring physiological insulin secretion through the use of technologies and insulins that are increasingly closer to the physiological kinetics of human insulin. The means available today are: new insulins, devices for blood glucose monitoring (CGM), smart insulin pens, and automatic insulin delivery systems (AID). All these systems provide healthcare professionals and caregivers with the ability to ensure continuous care, also thanks to the use of data sharing platforms that allow for almost continuous care with consequent satisfaction regarding patient care and better achievement of therapeutic goals.